The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.
The MarketWatch News Department was not involved in the creation of this content. This newly FDA-approved system offers a groundbreaking device for adults with RA. VENTURA, Calif., March 11, 2026 ...
New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results